OBJECTIVES: To assess overall resistance rates and risk factors for resistance to ampicillin, co-amoxiclav, nalidixic acid, fluoroquinolones and trimethoprim/sulfamethoxazole in Escherichia coli strains isolated from outpatients with acute urinary tract infection in Dakar (Senegal). PATIENTS AND METHODS: From June 2001 to June 2003, a prospective study was performed among Senegalese outpatients consulting at the Institut Pasteur of Dakar for urine analysis. Evaluated risk factors were: age, gender, prior hospitalization, antibiotic exposure, urinary tract infection and urinary catheter. RESULTS: A total of 398 non-duplicate, consecutive, biologically significant E. coli were isolated. The levels of antibiotic resistance in Dakar appeared dramatic and worrisome with resistance rates ranging from 18.6% for fluoroquinolones to 73.6% for ampicillin. With the exception of the presence of urinary catheter, the risk factors identified were consistent with data previously reported in developed countries. CONCLUSIONS: We hope our results will assist medical authorities in the development of appropriate control strategies.
OBJECTIVES: To assess overall resistance rates and risk factors for resistance to ampicillin, co-amoxiclav, nalidixic acid, fluoroquinolones and trimethoprim/sulfamethoxazole in Escherichia coli strains isolated from outpatients with acute urinary tract infection in Dakar (Senegal). PATIENTS AND METHODS: From June 2001 to June 2003, a prospective study was performed among Senegalese outpatients consulting at the Institut Pasteur of Dakar for urine analysis. Evaluated risk factors were: age, gender, prior hospitalization, antibiotic exposure, urinary tract infection and urinary catheter. RESULTS: A total of 398 non-duplicate, consecutive, biologically significant E. coli were isolated. The levels of antibiotic resistance in Dakar appeared dramatic and worrisome with resistance rates ranging from 18.6% for fluoroquinolones to 73.6% for ampicillin. With the exception of the presence of urinary catheter, the risk factors identified were consistent with data previously reported in developed countries. CONCLUSIONS: We hope our results will assist medical authorities in the development of appropriate control strategies.
Authors: Claude Mambo Muvunyi; Florence Masaisa; Claude Bayingana; Léon Mutesa; André Musemakweri; Grégoire Muhirwa; Geert W Claeys Journal: Am J Trop Med Hyg Date: 2011-06 Impact factor: 2.345
Authors: Daniel J Morgan; Iruka N Okeke; Ramanan Laxminarayan; Eli N Perencevich; Scott Weisenberg Journal: Lancet Infect Dis Date: 2011-06-12 Impact factor: 25.071
Authors: Rustom P Manecksha; Gregory J Nason; Ivor M Cullen; Jérôme P Fennell; Elizabeth McEvoy; Ted McDermott; Robert J Flynn; Ronald Grainger; John A Thornhill Journal: ScientificWorldJournal Date: 2012-05-02